Pharmafocus April/May 2025 - Magazine Contents

Belgium biotechnology company Galapagos has made changes at the top as it prepares to split into two separate entities.

www.pmlive.com/awards/communique/book_a_table

Germany, France, Belgium, Italy and the Netherlands account for the majority of trade in pharmaceutical products across Europe, according to a new report.

PharmaRole.com

Welcome to the April/May issue of Pharmafocus, which arrives at a time when established scientific and trade norms are being upended under the current US administration. So, it’s timely that a new report should emerge that examines pharmaceutical trade across Europe and delves into the largest international markets for our industry (page 4).

Besins Healthcare has launched in the UK its new treatment, based on progesterone, to prevent miscarriage.

Two biotech firms and a radiochemistry company will develop next-generation targeted alpha-therapies to treat various forms of cancer.

After TauRx Pharmaceutics’ investigational Alzheimer’s treatment hydromethylthionine mesylate (HMTM) was found to slow the disease’s progression it could, if approved, become the first oral treatment targeting the tau protein.

Novo Nordisk’s diabetes treatment Rybelsus (semaglutide) has been found to significantly reduce the risk of major adverse cardiovascular events (MACE).

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Moderna’s plans to manufacture commercial mRNA vaccines at its existing facility in Harwell in Oxfordshire.

Indian biotechnology company Eyestem Research has achieved successful results from a phase 1 trial of Eyecyte-RPE, its potential therapy for a rare, advanced form of dry age-related macular degeneration (AMD).